

10. REFERENCES

Agusti AGN, Noguera A, Sauleda J, Sala E, Pons J, Bousquets X. Systemic effects of chronic obstructive pulmonary disease. *Eur Respir J* 2003;21:347-360.

American Thoracic Society. Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Medicine* 1995;152:S77-S120.

Almagro P, Calbo E, Ochoa de Echaguen A *et al.* Mortality after hospitalization for COPD. *Chest* 2002; 121: 1441-48.

Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. *Eur Respir J* 2001; 17: 982-94.

Anthonisen A, Manfreda J, Warren C, Hershfield E, Harding G, Nelson N . Antibiotic Therapy in Exacerbations of Chronic Obstructive Pulmonary Disease. *Annals of Internal Medicine* 1987;106:196-204.

Anthonisen NR, Connett JE, Muruay RP. Smoking and Lung Function of Lung Health Study Participants. *American Journal of Respiratory & Critical Care Medicine* 2002;166(3):675-679.

Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. *American Review of Respiratory Disease* 1986;133(1):14-20.

Barnette MS. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). *Progress in Drug Research* 1999;53:193-229.

Barnette, M. S., Christensen, S.B., Essayan, D.M., Grous, M., Prabhakar, U., Rush, J.A., Kagey-Sobotka, A. and Torphy, T.J. SB 207499 (Ariflo), a potent and selective second generation phosphodiesterase 4 inhibitors: in vitro anti-inflammatory actions. *J. Pharmacol. Exp. Ther* 1998;284:420-426

Belman, M. J., W. C. Botnick, and J. W. Shin. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1996;153:967-975.

Borg G. Psychophysical Bases of Perceived Exertion. *Medicine and Science in Sports and Exercise* 1982;14(5):377-381.

Brook RH, Ware JE Jr, Davies-Avery A, Stewart AL, Donald CA, Rogers WH. Conceptualization and measurement of health for adults in the health insurance study. Vol. VIII, overview. Santa Monica, Calif.: Rand Corporation, 1979. (Publication no. R-1987/3-HEW.)

Brook RH, Ware JE Jr, Rogers WH *et al.* Does free care improve adults' health? Results from a randomized controlled trial. *N Engl J Med.* 1983; 309:1426-34.

- Brugman TM, Morris JF, Temple WP. Comparison of lung volume measurements by single breath helium and multiple breath nitrogen equilibration methods in normal subjects and COPD patients. *Respiration*. 1986;49(1):52-60.
- Burns CB, Scheinhorn DJ. Evaluation of single-breath helium dilution total lung capacity in obstructive lung disease. *Am Rev Respir Dis* 1984;130(4):580-3.
- Church MK, Featherstone RL, Cushley MJ, Mann JS and Holgate ST. Relationships between adenosine, cyclic nucleotides and xanthines in asthma. *Journal of Allergy and Clinical Immunology* 1986;78:670-675.
- Collins JJ et al. Subchronic toxicity of orally administered (gavage and dosed-feed) theophylline in Fischer 344 rats and B6CF1 mice. *Fundam Appl Toxicol* 1988;11:472-484.
- Coultas DB, Mapel D, Gagnon R, Lydick E. The health impact of undiagnosed airflow obstruction in a national sample of United States adults. *Am J Respir Crit Care Med* 2001; 164: 372-377.
- Crapo RO, Morris AH, Gardiner RM. 1981. Reference Spirometric Values Using Techniques and Equipment that Meet ATS Recommendations. *Am Rev Respir Dis* 1981;123:659-664.
- Crapo R. Pulmonary function testing. In: *Textbook of Pulmonary Diseases*, 6th ed. Edited by GL Baum, RR Celli, JB Karlinsky, Lippencott-Raven Publishers, Philadelphia 1998.
- DeWolf, W.E., Burman, M., Cieslinski, L.B. and Torphy T.J. Dec 1994; Christensen, S.B., Guider, A., Forster, C.J., Gleason, J.G., Bender, P.E., Karpinski, J.M. et al. 1,4-cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. *J. Med. Chem.* 1998;41:821-835.
- DiStefano A, Maestrelli P, Roggeri A, Turato G, Calabro S, Potena A, et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. *Am J Respir Crit Care Med* 1994;149(3 Pt 1):803-10.
- Friedman L et al. Testicular atrophy and impaired spermatogenesis in rats fed high levels of methylxanthines caffeine, theobromine or theophylline. *J. Environ. Pathol. Toxicol* 1979;2:687-706.
- Fuso L, Incalzi RA, Pistelli R *et al.* Predicting mortality of patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. *Am J Med* 1995; 98: 272-7.
- Gonzalez S, Hards J, van Eeden S, Hogg JC. The expression of adhesion molecules in cigarette smoke-induced airways obstruction. *Eur Respir J* 1996;9(10):1995-2001.
- Grashoff WF, Sont JK, Sterk PJ, Hiemstra PS, de Boer WI, Stolk J, et al. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. *Am J Path* 1997;151(6):1785-90.

GlaxoSmithKline Worldwide Epidemiology. Incidence of Colon Ischemia and Perforated Intestine Among a Cohort of Patients with Chronic Obstructive Pulmonary Disease: Revised Report. GSK Report EPI 40259, April 1, 2003. Study conducted by Ingenix Epidemiology Division, A UnitedHealth Group Company on behalf of GSK.

GlaxoSmithKline Worldwide Epidemiology. The Prevalence and Incidence of Cardiovascular Diseases Among Persons with Chronic Obstructive Pulmonary Disease in the Veterans Administration Medical System. GSK Report WE156, February 7, 2002. Study conducted by Douglas W. Mapel, University of New Mexico Health Sciences Center on behalf of GSK.

Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. *Can Med Assoc J* 1985;132:919-923.

Hansen EJ, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999;159:1267-1271

Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. *Chest* 2000; 118: 1278-85.

Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. *Biometrika* 1988;75:800-802.

Johansson S. Cardiovascular lesions in Sprague-Dawley rats induced by long-term treatment with caffeine. *Acta Pathol Microbiol Scand* 1981;89:185-191

Jones NL. *Approaches to Clinical Exercise Testing*, (3rd ed). Philadelphia: WB Saunders Company 1988.

Jones PW, Quirk FH, Baveystock CM. 1991. The St. George's Respiratory Questionnaire. *Respir Med* 1991;85(B):25-31

Joseph EC et al (1996) Mesenteric arteriopathy in the rat induced by phosphodiesterase inhibitors: an investigation of morphological, ultrastructural and hemodynamic changes. *Toxicol Path* 1996;24:436-450

Joseph EC et al. Pathogenesis of arterial lesions caused by vasoactive compounds in laboratory animals. In *Comprehensive Toxicology*, Sipes I.G. et al., editors. Elsevier, New York 1997, Vol. 6, Pages 285 and 302

Kendrick AH. Comparison of methods of measuring static lung volumes. *Monaldi Archives for Chest Disease* 1996;51(5):431-9.

Kerns WD et al (1989) Pathogenesis of arterial lesions induced by dopaminergic compounds in the rat. *Toxicol Pathol* 1989;17:205-214.

- Kohyama, T., Lui, X., Wen F-Q., Zhu, Y. K. et al. 2002. PDE4 Inhibitors Attenuate Fibroblast Chemotaxis and Contraction of Native Collagen Gels. *American Journal of Respiratory Cell and Molecular Biology* 2002;26:694-701.
- Kumari M, Cover PO, Poyser RH et al. Stimulation of the Hypothalamo-Pituitary-Adrenal Axis in the Rat by Three Selective Type-4 Phosphodiesterase Inhibitors: In Vitro and in Vivo Studies. *Brit J Pharmacol* 1997;121:459-468
- Lacoste JY. Bousquet J. Chanez P. Van Vyve T. Simony-Lafontaine J. Lequeu N. Vic P. Enander I. Godard P. Michel FB. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 1993;92(4):537-48.
- Larson JL et al (1996) The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. *Pharmacol. Toxicol*, **78**, 44-49
- Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. *Chest* 1999;115(4):957-65.
- Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease. *Arch Intern Med* 2000; 160: 2653-8.
- Mapel DW, Dedrick DL. Prevalence and incidence of serious cardiovascular complications among COPD patients. *Am J Respir Crit Care Med* 2002;165(8):A446.
- Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic Obstructive Pulmonary Disease Surveillance—United States, 1971-2000. In: *Surveillance Summaries*, August 2, 2002. *MMWR* 2002;51(No. SS06):1-16.
- Mannino DM, Buist AS, Petty TL, Redd SC. Lung function and mortality in the United States: data from the first National Health and Nutrition Examination Survey follow up study. *Thorax* 2003; 58: 388-393.
- Miller A. Single-breath helium dilution method in obstructing lung disease. *Am Rev Respir Dis*. 134(3):634, 1986.
- Morton D, Weisbrode SE, Wyder WE et al. (1986) Spermatid Giant Cells, Tubular Hypospermatogenesis, Spermogonial Swelling, Cytoplasmic Vacuoles, and Tubular Dilatation in the Testes of Normal Rabbits. *Veterinary Pathology*, **23**, 176-183
- Murray CJL, Lopez AD, eds. *The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020*. Cambridge, MA. Harvard School of Public Health on behalf of WHO/World Bank (Global burden of disease and injury series, Vol 1). 1996.
- Nagai, A, Thurlbeck WM. Scanning electron microscopic observations of emphysema in humans. A descriptive study. *Am Rev Respir Dis* 1991;144:901-908.

National Center for Health Statistics. Health, United States, 2001 with Urban and Rural Chartbook. Hyattsville, Maryland: 2001.

National Heart Lung and Blood Institute (NHLBI Chartbook). *Morbidity and Mortality Chartbook on Cardiovascular, Lung and Blood Diseases, 2002.*

NHLBI/WHO Workshop Report: Global Strategy for the Diagnosis, Management, and Prevention of COPD. Scientific information and recommendations for COPD programs. NIH Publication number 2701. April 2001.

Newton MF, O'Donnell DE, Forkert L. 2002. Response of Lung Volumes to Inhaled Salbutamol in a Large Population of Patients with Severe Hyperinflation. CHEST; 121: 1042-1050.

O'Donnell, D.E. Assessment of bronchodilator efficacy in symptomatic COPD: Is spirometry useful? CHEST 2000;117:42S-47S.

O'Donnell, D.E., Forkert L., and Webb, K. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 2001;18:914-920.

O'Donnell, D.E., Lam M., and Webb, K. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542-549.

O'Donnell, D. E., M. Lam, and K. A. Webb. 1998. Measurement of symptoms, lung hyperinflation and endurance during exercise in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 158:1557-1565.

O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-777.

Patrick DL, Bush JW, Chen MM. Toward an operational definition of health. J Health Soc Behav. 1973;14:6-23.

Pesci A, Balbi B, Majori M, Cacciani G, Bertacco S, Alciato P, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Resp J 1998;12(2):380-6.

Petty TL. Scope of the COPD problem in North America: early studies of prevalence and NHANES III data: basis for early identification and intervention. Chest 2000;117 (5 Suppl 2):326S-331S.

Postma DS and Sluiter, HJ. Prognosis of chronic obstructive pulmonary disease: the Dutch experience. American Review of Respiratory Disease 1989;140: S100-S105.

- Postma DS, Gimeno F, van der Weele LT, Sluiter HJ. Assessment of ventilatory variables in survival prediction of patients with chronic airflow obstruction: the importance of reversibility. *Eur.J. Respir. Dis.* 1985;67:360–368.
- Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory & Critical Care Medicine* 2001;163(5):1087-92
- Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciruba FC, Rogers RM, Hayashi S, Hogg JC. Amplification of inflammation in emphysema and its association with latent adenoviral infection. *Am J Respira Crit Care Med* 2001;164: 469-473.
- Rutgers SR, Timens W, Kauffman HF, Postma DS. (2001) Markers of active airway inflammation and remodelling in chronic obstructive pulmonary disease. *Clinical & Experimental Allergy* 2001;31(2):193-205.
- Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. *Am J Resp Crit Care Med* 1999;160(2):711-7.
- Saetta M, Di Stefano A, Maestrelli P, Ferraresso A, Drigo R, Potena A, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. *Am Rev Respir Dis* 1993;147(2):301-6.
- Sandusky GE and Means JR. Acute and subacute toxicology of LY-195115 in rats and dogs. *Tox Letters* 1987;38:177-186.
- Sandusky GE, Franklin RB and Means JR. Acute, subchronic and chronic toxicity of the cardiotonic isomazole in rats. *Fundam Appl Toxicol* 1989;13:409-417.
- Seemungal T, Donaldson G, Paul E, Bestall J, Jeffries D, Wedzicha J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. *American Journal of Critical Care Medicine* 1998;157:1418-1422.
- Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory & Critical Care Medicine* 2000;161(5):1608-13.
- Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, MacCallum P, Meade T, Jeffries D, Johnston SL, Wedzicha J. Respiratory Viruses, Symptoms, and Inflammatory Markers in Acute Exacerbations and Stable Chronic Obstructive Pulmonary Disease. *American Journal of Critical Care Medicine* 2001;164:1618-1623.
- Soriano JB, Maier WC, Egger P *et al.* Recent trends in physician diagnosed COPD in men and women in the UK. *Thorax* 2000; 55: 789-94.

Spencer S, Calverley P, Burge S, Jones P on behalf of the ISOLDE Study Group Health Status Deterioration in Patients with Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2001;163:122-128.

Thompson AB, Daughton D, Robbins RA, Ghafouri MA, Oehlerking M, Rennard SI. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. *Am Rev Respir Dis* 1989;140(6):1527-37.

Torphy TJ. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. *American Journal of Respiratory and Critical Care Medicine* 1998;157:351-370.

Torphy TJ and Udem BJ. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. *Thorax* 1991;46:512-523.

Torphy, TJ. and Livi GP. Phosphodiesterase isozymes in airways. In: *Lung Biology in Health and Disease*. In: *Pharmacology of the Respiratory Tract: Clinical and Experimental*, edited by C. Lenfant, series ed., KF Chung, and PJ Barnes. New York: Marcel Dekker Inc. 1993;177-221.

Turato G, Zuin R, Miniati M, Barbaldo S, Rea F, Beghe B, Monti S, Formichi B, Boschetto P, Harari S, Papi A, Maestrelli P, Fabbri LM, Saetta M. Airway inflammation in severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2002;166:105-110

Underwood, D.C., Bochnowicz, S., Osborn, R.R., Kotzer, C.J., Luttmann, M.A., Hay, D.W.P., Gorycki, P.D., Christensen, S.B., Torphy, T.J. Antiasthmatic activity of the second generation phosphodiesterase 4 (PDE4) inhibitor, SB 207499 (Ariflo) in the guinea pig. *J. Pharmacol. Exp. Ther.* 1998;287: 988-995.

van Manen JG, Bindels PJ, IJzermans CJ, van der Zee JS, Bottema BJ, Schade E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. *Journal of Clinical Epidemiology* 2001;54(3):287-93.

Westwood FR, Iswaran TJ and Greaves P. Pathologic changes in blood vessels following administration of an inotropic vasodilator (ICI 153,110) to the rat. *Fundam Appl Toxicol* 1990;14:797-809.

Wildman M, Groves J, Walia S, Stableforth D, Ayres J. Hospitalised COPD exacerbations: survival and univariate outcome predictors, 36-month follow up. *Am J Respir Crit Care Med* 2002; 165: A272.

Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, et al. Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. *Am J Respir Crit Care Med* 2001;164(1):109-16.